Work

Novel Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion-Selective Inhibitors for Lung Cancer Therapy

Year: 2026

Type: editorial

Abstract: This patent describes novel prop-2-ynamide-derived epidermal growth factor receptor (EGFR) inhibitors, which selectively target EGFR exon20 insertion mutations. These EGFR inhibitors exhibit therapeutic potential for the treatment of nonsmall cell lung cancer (NSCLC) and other malignancies driven by EGFR mutations.

Source: ACS Medicinal Chemistry Letters

DOI: 10.1021/acsmedchemlett.6c00030

Authors: Yanwei Jiang, Steven H. Liang

Institutions: Emory University, Georgia Institute of Technology, The Wallace H. Coulter Department of Biomedical Engineering

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7128453406

Cites: 8

Cited by:

Related to: